Clinical Study

Ea9181 A Phase III Randomized Trial Of Steroids+Tyrosine Kinase Inhibitor Induction With Chemotherapy Or Blinatumomab For Newly Diagnosed Bcr-Abl-Positive Acute Lymphoblastic Leukemia In Adults

Posted Date: Jul 13, 2021

  • Investigator: Emily Curran
  • Specialties: Cancer, Leukemia, Oncology
  • Type of Study: Drug

This trial will compare the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. Efficacy will be measured by overall survival.


Patient Must Have Bcr-Abl1 Positive Disease. Total Bilirubin =< 3 Mg/Dl. Estimated Creatinine Clearance > 45 Mg/Min. Patients Must Be Class 2B Or Better. Patient Must Not Have Received Chemotherapy For B-All. No Active Central Nervous System (Cns) Involvement By Leukemic Blasts. No Active Concomitant Malignancy.


Phase 3, Leukemia

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.